三重再攝取抑制劑
此條目需要擴充。 (2015年9月29日) |
血清素-去甲腎上腺素-多巴胺再攝取抑制劑（英語：serotonin–norepinephrine–dopamine reuptake inhibitor，SNDRI），也稱作三重再攝取抑制劑（TRI），是多種單胺類神經遞質的再攝取抑制劑，原理為通過抑制5-羥色胺轉運體、去甲腎上腺素轉運體和多巴胺轉運體體來分別抑制5-羥色胺、 去甲腎上腺素和多巴胺的再攝取。這個作用會增加這些神經遞質在突觸間隙的濃度。
SNDRI作為一系列疾病的藥物候選而被開發，如抗憂鬱劑[1][2][3][4][5] 和治療肥胖、可卡因成癮、注意力缺陷/過動症(ADHD)及慢性疼痛的藥物。SNDRI作為選擇性血清素再吸收抑制劑(SSRIs)及血清素-去甲腎上腺素再吸收抑制劑(SNRIs)的延伸，增加了多巴胺的再吸收抑制作用，這被認為具有增加療效的可能，但副作用及藥物濫用的可能也隨之增加。
引用
- ^ Musk, P. Magic shotgun methods for developing drugs for CNS disorders. Discovery medicine. 2004, 4 (23): 299–302. PMID 20704963.
- ^ Millan, MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2009, 6 (1): 53–77. PMID 19110199. doi:10.1016/j.nurt.2008.10.039.
- ^ Chen, Z; Skolnick, P. Triple uptake inhibitors: Therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs. 2007, 16 (9): 1365–77. PMID 17714023. doi:10.1517/13543784.16.9.1365.
- ^ Perona, MT; Waters, S; Hall, FS; Sora, I; Lesch, KP; Murphy, DL; Caron, M; Uhl, GR. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions. Behavioural Pharmacology. 2008, 19 (5–6): 566–74. PMC 2644662
. PMID 18690111. doi:10.1097/FBP.0b013e32830cd80f.
- ^ Chen, Z; Yang, J; Tobak, A. Designing new treatments for depression and anxiety. IDrugs : the investigational drugs journal. 2008, 11 (3): 189–97. PMID 18311656.
